AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31241007 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nano‐curcumin (80 mg) plus CoQ10 (300 mg)
Number of subjects: 100
Study 31241007 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano‐curcumin (80 mg)
Number of subjects: 100
Study 31241007 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 (300 mg)
Number of subjects: 100
Study 31241007 — intervention group
Group type: COMPARATOR
Intervention: Control (nano‐curcumin and CoQ10 placebo included oral paraffin oil)
Number of subjects: 100
Study 29628182 — intervention group
Group type: EXPERIMENTAL
Intervention: Time In intervention (sensorimotor intervention combining biomechanical physiotherapeutic procedures and psychological strategies, 3h weekly sessions for 5 weeks)
Number of subjects: 40
Study 29628182 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 40
Study 29302694 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video game (binocular falling-blocks video game) played for 1 hour per day for 6 weeks.
Number of subjects: 115
Study 29302694 — intervention group
Group type: COMPARATOR
Intervention: Placebo video game played for 1 hour per day for 6 weeks.
Number of subjects: 115
Study 29302694 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video game (binocular falling-blocks video game)
Number of subjects: 115
Study 29302694 — intervention group
Group type: COMPARATOR
Intervention: Placebo video game
Number of subjects: 115
Study 26752109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine (20 mg/day)
Number of subjects: 55
Study 26752109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 24132766 — intervention group
Group type: COMPARATOR
Intervention: Software Package 1 (P1)
Number of subjects: 50
Study 24132766 — intervention group
Group type: EXPERIMENTAL
Intervention: Software Package 2 (P2)
Number of subjects: 50
Study 24132766 — intervention group
Group type: EXPERIMENTAL
Intervention: Software Package 3 (P3)
Number of subjects: 50
Study 22305273 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation
Number of subjects: 10
Study 22305273 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 10
Study 18635703 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 28611 3-10 microg/kg
Number of subjects: 0
Study 18635703 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.1 mg/kg
Number of subjects: 0
Study 18635703 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 28611 up to 1 microg/kg
Number of subjects: 0
Study 18635703 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 28611 above 3 microg/kg
Number of subjects: 0
Study 17224707 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (2.5 mg)
Number of subjects: 15
Study 17224707 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg)
Number of subjects: 15
Study 17224707 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg)
Number of subjects: 15
Study 17224707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15711670 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) alfa 2b 3 million units 3 times per week plus ribavirin 1000-1200 mg orally per day for 48 weeks
Number of subjects: 62
Study 15711670 — intervention group
Group type: COMPARATOR
Intervention: Interferon (IFN) alfa 2b alone
Number of subjects: 62
Study 12109933 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 0
Study 9740342 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 121
Study 9740342 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nitroglycerin
Number of subjects: 121
Study 7859421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 50 mg/kg (single dose)
Number of subjects: 54
Study 7859421 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 40 mg/kg/day (10 days)
Number of subjects: 54
Study 2816761 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (7 mg/kg)
Number of subjects: 10
Study 2816761 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (10 mg)
Number of subjects: 10
Study 128475 — intervention group
Group type: EXPERIMENTAL
Intervention: Locacorten (0.02%)-Vioform (3%) cream
Number of subjects: 430
Study 128475 — intervention group
Group type: COMPARATOR
Intervention: Vioform 3%
Number of subjects: 430
Study 128475 — intervention group
Group type: COMPARATOR
Intervention: Locacorten 0.02%
Number of subjects: 430
Study 128475 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 430
Study 31607400 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery (ultrasound motor tips)
Number of subjects: 15
Study 31607400 — intervention group
Group type: COMPARATOR
Intervention: Conventional rotary instrument
Number of subjects: 15
Study 28606085 — intervention group
Group type: EXPERIMENTAL
Intervention: One4All strategy (intervention arm)
Number of subjects: 180
Study 28606085 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control arm)
Number of subjects: 180
Study 24902962 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pioglitazone 30 mg daily for 10 weeks
Number of subjects: 48
Study 24902962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23132643 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidic saline (2.5 mL, pH 3.3)
Number of subjects: 18
Study 23132643 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (2.5 mL, pH 6.0)
Number of subjects: 18
Study 23132643 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (acidic saline and isotonic saline)
Number of subjects: 18
Study 21640683 — intervention group
Group type: EXPERIMENTAL
Intervention: Social determinants of health curriculum (intervention)
Number of subjects: 38
Study 21640683 — intervention group
Group type: COMPARATOR
Intervention: Control group (prior year interns)
Number of subjects: 38
Study 19787598 — intervention group
Group type: EXPERIMENTAL
Intervention: ICare
Number of subjects: 93
Study 19787598 — intervention group
Group type: EXPERIMENTAL
Intervention: DCT
Number of subjects: 93
Study 19787598 — intervention group
Group type: EXPERIMENTAL
Intervention: ORA (Goldmann-correlated IOP)
Number of subjects: 93
Study 19787598 — intervention group
Group type: COMPARATOR
Intervention: GAT
Number of subjects: 93
Study 19787598 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' preference
Number of subjects: 93
Study 16411869 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking with a dog
Number of subjects: 13
Study 16411869 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction with the dog at home
Number of subjects: 13
Study 16411869 — intervention group
Group type: COMPARATOR
Intervention: Walking without a dog
Number of subjects: 13
Study 15235937 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anaesthesia (LA)
Number of subjects: 138
Study 15235937 — intervention group
Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 138
Study 15235937 — intervention group
Group type: COMPARATOR
Intervention: Regional Anaesthesia (RA)
Number of subjects: 138
Study 11244441 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide (Men PS) vaccine, administered 8 months after BMT (early group; 22 patients)
Number of subjects: 44
Study 11244441 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide (Men PS) vaccine, administered 20 months after BMT (late group; 22 patients)
Number of subjects: 44
Study 11244441 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide (Men PS) vaccine, both early and late groups
Number of subjects: 44
Study 9855434 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-component acellular vaccine (3-5-12 schedule)
Number of subjects: 72898
Study 9855434 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-component vaccine (3-5-12 schedule)
Number of subjects: 72898
Study 9855434 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-cell vaccine (3-5-12 schedule)
Number of subjects: 72898
Study 9855434 — intervention group
Group type: COMPARATOR
Intervention: Multicomponent acellular vaccine (2-4-6 schedule)
Number of subjects: 72898
Study 9855434 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed third dose (both schedules)
Number of subjects: 72898
Study 8080071 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant interferon‐gamma (rIFN‐gamma)
Number of subjects: 212
Study 8080071 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 212
Study 2759604 — intervention group
Group type: EXPERIMENTAL
Intervention: Aylesbury spatula
Number of subjects: 4079
Study 2759604 — intervention group
Group type: COMPARATOR
Intervention: Ayre spatula
Number of subjects: 4079
Study 263815 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific support for grief and encouragement of mourning during the first three months
Number of subjects: 200
Study 263815 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 200
Study 263815 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific support for grief and encouragement of mourning
Number of subjects: 200
Study 31481010 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal epidural injection (TEI) with lidocaine and methylprednisolone acetate for L3 and below, and lidocaine with dexamethasone above L3.
Number of subjects: 142
Study 31481010 — intervention group
Group type: COMPARATOR
Intervention: Standard oral pain medication.
Number of subjects: 142
Study 28058505 — intervention group
Group type: EXPERIMENTAL
Intervention: six‐session couple‐separated psycho‐educational program
Number of subjects: 352
Study 28058505 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 352
Study 25541084 — intervention group
Group type: EXPERIMENTAL
Intervention: External ventricular drain (EVD)
Number of subjects: 122
Study 25541084 — intervention group
Group type: COMPARATOR
Intervention: Intraparenchymal fiberoptic monitor (IPM)
Number of subjects: 122
Study 24995271 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg), amoxicillin/clavulanate (875 mg/125 mg), and rabeprazole (20 mg) twice per day (LAcR)
Number of subjects: 146
Study 24995271 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin (500 mg), amoxicillin (1000 mg), and rabeprazole (20 mg) twice per day (CAR)
Number of subjects: 146
Study 22766314 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m² intravenously day 1 with vitamin B12, folic acid, and dexamethasone
Number of subjects: 260
Study 22766314 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m² intravenously day 1 with dexamethasone
Number of subjects: 260
Study 18849664 — intervention group
Group type: EXPERIMENTAL
Intervention: DTwP/HB vaccine (Q‐Vac) administered alone (Group A)
Number of subjects: 447
Study 18849664 — intervention group
Group type: EXPERIMENTAL
Intervention: DTwP and HB vaccines at separate sites (Group B)
Number of subjects: 447
Study 18849664 — intervention group
Group type: COMPARATOR
Intervention: DTPw/HB vaccine (Tritanrix HB) (Group C)
Number of subjects: 447
Study 17719471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg for 6 weeks
Number of subjects: 20
Study 17719471 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg for 6 weeks
Number of subjects: 20
Study 15498107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell ELISA assay using 30-kD protein antigen
Number of subjects: 12
Study 11427774 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic physical training
Number of subjects: 0
Study 11427774 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic physical training at 40-50% intensity
Number of subjects: 0
Study 11427774 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity exercise
Number of subjects: 0
Study 9250598 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise after a meal with suspected food ingestion
Number of subjects: 6
Study 9250598 — intervention group
Group type: COMPARATOR
Intervention: Exercise after a meal without suspected food ingestion
Number of subjects: 6
Study 9250598 — intervention group
Group type: COMPARATOR
Intervention: Suspected foods only
Number of subjects: 6
Study 8483071 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound instillation with 0.25% bupivacaine
Number of subjects: 70
Study 8483071 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal block with 0.25% bupivacaine
Number of subjects: 70
Study 8483071 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 3319721 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of grenz ray treatment and topical steroid
Number of subjects: 17
Study 3319721 — intervention group
Group type: COMPARATOR
Intervention: Topical steroid alone
Number of subjects: 17
Study 30630789 — intervention group
Group type: EXPERIMENTAL
Intervention: External application of Ji De Sheng She Yao and minimally invasive surgery
Number of subjects: 160
Study 30630789 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of cefmetazole and traditional excision
Number of subjects: 160
Study 27565283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranking method (5 health states)
Number of subjects: 300
Study 27565283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranking method (4 health states)
Number of subjects: 300
Study 27565283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranking method (3 health states)
Number of subjects: 300
Study 27565283 — intervention group
Group type: COMPARATOR
Intervention: Paired comparison method
Number of subjects: 300
Study 24368363 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy (usual care plus two additional 30-minute treatments each day)
Number of subjects: 90
Study 24368363 — intervention group
Group type: COMPARATOR
Intervention: Usual care (daily physiotherapy treatment, approximately 30 minutes)
Number of subjects: 90
Study 24368363 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy
Number of subjects: 90
Study 22439657 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced expectancy group (provided with fabricated feedback about running efficiency every 2 min)
Number of subjects: 2
Study 22439657 — intervention group
Group type: COMPARATOR
Intervention: Control group (not given feedback)
Number of subjects: 2
Study 22439657 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced expectancy group
Number of subjects: 2
Study 22439657 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study 20857782 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% silver sulphadiazine and 5% chlorhexidine dressing
Number of subjects: 38
Study 20857782 — intervention group
Group type: COMPARATOR
Intervention: 5% chlorhexidine dressing alone
Number of subjects: 38
Study 18235122 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose imatinib (400 mg daily)
Number of subjects: 746
Study 18235122 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose imatinib (400 mg twice daily)
Number of subjects: 746
Study 18235122 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose imatinib (400 mg daily) followed by high-dose imatinib (400 mg twice daily) after progression
Number of subjects: 746
Study 15653971 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP), 1,000 microg/d, then reduced to 200 microg/d (group 1)
Number of subjects: 35
Study 15653971 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose of FP, 200 microg/d (group 2)
Number of subjects: 35
Study 12608491 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic beer (8.5%) administered to reach a blood alcohol concentration of 40 mg/dl
Number of subjects: 48
Study 12608491 — intervention group
Group type: COMPARATOR
Intervention: Placebo beer (equivalent volume to alcoholic beer)
Number of subjects: 48
Study 10440421 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily for 10 days
Number of subjects: 20
Study 10440421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8909632 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 1: General enhancement classroom intervention
Number of subjects: 0
Study 8909632 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 2: Intensive small-group sessions for at-risk children
Number of subjects: 0
Study 8909632 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 3: One-year family relationship intervention
Number of subjects: 0
Study 8909632 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 1316060 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg oral lomefloxacin 2-6 hours before surgery
Number of subjects: 63
Study 1316060 — intervention group
Group type: COMPARATOR
Intervention: 1.5 g parenteral cefuroxime 30-90 minutes before surgery
Number of subjects: 63
Study 1316060 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg oral lomefloxacin
Number of subjects: 63
Study 1316060 — intervention group
Group type: COMPARATOR
Intervention: 1.5 g parenteral cefuroxime
Number of subjects: 63
Study 3904259 — intervention group
Group type: EXPERIMENTAL
Intervention: Live, attenuated cold‐adapted influenza A vaccines (H1N1 and H3N2)
Number of subjects: 0
Study 31554075 — intervention group
Group type: EXPERIMENTAL
Intervention: GanedenBC30 (1 × 10^9 colony-forming units)
Number of subjects: 80
Study 31554075 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 80
Study 29769106 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-to-peer mentoring (MBA)
Number of subjects: 20
Study 29769106 — intervention group
Group type: COMPARATOR
Intervention: Teacher-led (PBA)
Number of subjects: 20
Study 26872892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib administered after a high-fat meal
Number of subjects: 24
Study 26872892 — intervention group
Group type: COMPARATOR
Intervention: Ixazomib administered in fasted state
Number of subjects: 24
Study 26169304 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine treatment
Number of subjects: 90
Study 23315999 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief eclectic psychotherapy for PTSD (successful treatment group, n = 10)
Number of subjects: 45
Study 23315999 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief eclectic psychotherapy for PTSD (unsuccessful treatment group, n = 10)
Number of subjects: 45
Study 19756773 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate (MA)
Number of subjects: 80
Study 19756773 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) plus olanzapine (OLN)
Number of subjects: 80
Study 17938943 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chlormadinone acetate
Number of subjects: 40
Study 17938943 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular progesterone
Number of subjects: 40
Study 16669976 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg/d (FA-5)
Number of subjects: 17
Study 16669976 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 15 mg/d (FA-15)
Number of subjects: 17
Study 12796671 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg fluoxetine once weekly
Number of subjects: 80
Study 12796671 — intervention group
Group type: COMPARATOR
Intervention: 20 mg fluoxetine daily
Number of subjects: 80
Study 11370345 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg aqueous extract powder in 10 mL distilled water
Number of subjects: 20
Study 11370345 — intervention group
Group type: COMPARATOR
Intervention: 10 mL distilled water (control)
Number of subjects: 20
Study 8841891 — intervention group
Group type: EXPERIMENTAL
Intervention: Odontoson M plus an ionized irrigant solution
Number of subjects: 8
Study 8841891 — intervention group
Group type: COMPARATOR
Intervention: Widman flap type surgical technique
Number of subjects: 8
Study 1617924 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin
Number of subjects: 142
Study 1617924 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 142
Study 6466047 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mL/kg of ethanol
Number of subjects: 46
Study 6466047 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1 mL/kg of ethanol
Number of subjects: 46
Study 6466047 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 46
Study 6466047 — intervention group
Group type: COMPARATOR
Intervention: Control (FHN)
Number of subjects: 46
Study 30944165 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent focal noninvasive transcranial magnetic stimulation and electroencephalography
Number of subjects: 0
Study 30944165 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy (best-validated treatment for PTSD)
Number of subjects: 0
Study 29355727 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 77
Study 29355727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 77
Study 27631861 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy with reflective practice by therapists
Number of subjects: 0
Study 27631861 — intervention group
Group type: COMPARATOR
Intervention: Group therapy without consideration of group dynamics
Number of subjects: 0
Study 24983187 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg spironolactone (MRB group)
Number of subjects: 86
Study 24983187 — intervention group
Group type: COMPARATOR
Intervention: 5 mg ramipril (RASB group)
Number of subjects: 86
Study 22212211 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based intervention delivered during three × one hour sessions over a three week period.
Number of subjects: 400
Study 22212211 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 400
Study 18547863 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (COLD)
Number of subjects: 11
Study 18547863 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast water immersion (CWI)
Number of subjects: 11
Study 18547863 — intervention group
Group type: COMPARATOR
Intervention: No recovery treatment (control)
Number of subjects: 11
Study 17983303 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable communities
Number of subjects: 0
Study 17983303 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable cities
Number of subjects: 0
Study 17983303 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential stability
Number of subjects: 0